Yimingangke-B (01541) receives milestone payment under the authorization and cooperation agreement with AXION BIO.

The Zhitong Financial APP news, Yimingangke-B (01541) announced that after the FDA approval for the phase I clinical trial of IMM2510/AXN-2510 in the United States, the company has received a milestone payment of 10 million US dollars from Instil. As of the date of this announcement, the total amount of payments received under the authorization and cooperation agreement has reached 30 million US dollars (including milestone payments), showing the continued progress and steadfast commitment between the company and Instil.